TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Composite of safety laboratory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sORP rate in sperm samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-adjusted adequate clinical and parasitological response (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pneumococcal pneumonia requiring hospitalisation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of pneumococcal meningitis
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in the number of micturitions per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of participants with abnormal retinal photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of participants with abnormal visual field test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Titer of allergen specific IgG4 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Health status, overall
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Days poor physical health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Days limited in usual activities due to health
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Placement accuracy of neonatal ETT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One year disease-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: difficult cholecystectomy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 6 Month Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Objective Tumor Response Based on GOG RECIST Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urinary excretion of 5-HIAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Chromogranin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of blood investigations in detecting anastomotic leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet (fruit/vegetable intake)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Cognitive assessments
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Neurological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mother's real life experience assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Global longitudinal strain of the left ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of women using NRT after prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrence of Diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Remembered Items
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Amplitude of Neural Oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Quality of Life (NQOL-DN) Questionnaire Results
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: knee flexion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Using WatchPAT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Using CBT-I Coach
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to first treatment escalation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Adverse Events Related to Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Numeric Pain Rating Score (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Numeric Pain Score (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardio-respiratory fitness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular Strength change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with decision making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Tremor Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of PVI after exclusive anatomic approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients free of AF after 12-month FU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection rate and accuracy of HR and RR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capability to detect patient turns, bed-exit and entries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change from baseline of Eczema Area and Severity Index (EASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Investigator's Global Assessment (IGA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change from baseline of Atopic Dermatitis Severity Index (ADSI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cuff pressure of the nasotracheal tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local recidivism or metastasis reappearance
Endpoint domain: Mortality/survival
Primary endpoint: Positive urinary sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 gpELISA Units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Measles Virus Antibody Levels >=255 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Mumps Virus Antibody Levels >=10 Units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Rubella Virus Antibody Levels >=10 International Units/mL (IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute change in supine SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive functioning: Attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Severity of Levodopa-Induced Dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Clinical outcomes (postoperative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative physiological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Vivitrol Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Eczema Severity and Area Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dilation of the pupil in millimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neurological Disability - Expanded Disability Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hamilton Depression Rating Scale-17
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Knee Extensor Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak Knee Flexor Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood levels of GW876008 and midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Four-fold increase in antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative abstinence duration (CAD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Beck's Depression Inventory (BDI) scores from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: early worsening of the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Joint Space Narrowing (Midpoint Method)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Radiographic Joint Space Narrowing (Surface-Fit Method)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Radiographic Joint Space Narrowing (Kiapour Method)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physician decision making
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Presence of Order for Opioid Pain Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time Taken for a Complete Resolution of the Chalaziosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Recurrences
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the overall Healthy Heart Score risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SMA activation level and connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Kinetics of circulating extracellular vesicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate visualization and access to the cervix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Thickness of coracoacromial ligament
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Sternal Wound Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of neoadjuvant radiotherapy with capecitabine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Partial-Onset Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from preoperative serum concentration of Heparan Sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from preoperative serum concentration of Syndecan-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from preoperative serum concentration of Hyaluronic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from preoperative serum concentration of Sphingosine-1-Phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appearance of B-lines on lung ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Early appearance of peripheral pitting edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c at Month 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of late severe GU and GI toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Shunt Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Mean maximum change in Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical examination of dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of molar relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with oral habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of 11C-choline PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of 11C-choline PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of 11C-choline PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of DCBCI0901 infusions
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Therapeutic Dose
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: testosterone Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: testosterone AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: testosterone T1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anastrozole Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anastrozole AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anastrozole T1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants experiencing safety related issues
Endpoint domain: Adverse events/effects
Primary endpoint: In-stent neointimal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Intensive Care readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recorded atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: probing pocket depth change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding on probing change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical attachment level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative Urinary Drug Screen for Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Urine Drug Screen for Buprenorphine and Norbuprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Drug Test for Buprenorphine and Norbuprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Air Toxics Mercapturic Acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-tz of Afatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Afatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum post-ibutilide QT-F and QT-Fram intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the QT-F and QT-Fram versus time curves during and for 1 hour following ibutilide infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the QT-F and QT-Fram versus time curves during and for 8 hours following ibutilide infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants with completed assessments
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from Baseline PTSD Symptom Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-procedure Minimal Lumen Diameter (MLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heavy Drinking Days/Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Symptom Severity / Clinician Administered PTSD Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal Umbilical Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Identification of specific markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Duration Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Acne-Specific Quality of Life Score at Week 20
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjects Requiring Retreatment During the Post-treatment Period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Retreatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain Quality Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) Rate at 24 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Balance Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Tension levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Achieved ASAS Partial Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved ASAS 5/6 Remission Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved BASDAI 50 Remission Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Disease-Free Status at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Disease-Free Status at Month 12 in Comparison to the Previous Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Relapse Rate at Month 12 in Comparison to the Previous Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective inhaler use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to rituximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to rituximab resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Capillary Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess Weight (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stroke volume variation (SVV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plethysmographic variability index (PVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Cured of Vaginal Trichmonas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Progression of dopaminergic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression of serotoninergic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of 28-day mortality associated with nutritional support
Endpoint domain: Mortality/survival
Primary endpoint: Kilocalories delivered by enteral and/or parenteral route
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of complications related with nutritional support
Endpoint domain: Adverse events/effects
Primary endpoint: Vitamin E Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acquisition of tumour tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma Cmax of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Circulating naïve and memory T cell count (CD45RA/CD45RO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T-cell function by ELISPOT assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acute rejection within 24 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Chronic Pain Acceptance Questionnaire (CPAQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: final clinical cure rate for the index lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of participants with weight normalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of participants with absence of eating disordered behaviors
Endpoint domain: Adverse events/effects